Global Opioid Use Disorder Market- Drivers
Rising prevalence of opioid use disorder
Rising prevalence of opioid use disorder among the population is expected to drive growth of the the global opioid use disorder market over the forecast period. For instance, in 2020, according to the data published by National Institute on Drug Abuse, an estimated 2.7 Mn people aged 12 or older, in the U.S. had an opioid use disorder (OUD) including 2.3 Mn people with a prescription opioid use disorder.
Increasing organic growth strategies such as product approval
Increasing organic growth strategies such as product approval by regulatory authorities to expand product portfolio of the key market players is expected to drive growth of the global opioid use disorder market over the forecast period. For instance, in April 2020, Amneal Pharmaceuticals, Inc., a pharmaceutical company, announced that it had received abbreviated new drug application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of butrans (buprenorphine) transdermal system, 5 mcg/hr, 7.5 mcg/hr, 10 mcg/hr, 15 mcg/hr and 20 mcg/hr. Amneal Pharmaceuticals, Inc. was granted the competitive generic Ttherapy (CGT) designation and 180 days of exclusivity for the 7.5 mcg/hr dose.
Global Opioid Use Disorder Market: Restraint
Opioid Use Disorder Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients